WAYNE, Pa., June 27 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) today announced that it has once again been recognized as one
of FORTUNE's "America's Fastest-Growing Small Public Companies". This is the
second year for Escalon's inclusion.
    Escalon Medical Corp was ranked 70th, with Fortune reporting an annual
revenue growth rate of 13.3% and earnings per share annual growth rate of
35.9% for the three year annual rate and an annual rate of total return of
61.3% for the three year period ending December 31, 2004.
    To construct the list, FORTUNE Small Business magazine worked with Zacks
Investment Services to select public companies with $200 million or less in
annual revenue and a stock price of more $1.  These companies were then ranked
by earnings growth, revenue growth and stock performance over the last three
years.  Those rankings, which appear in the June/July issue, were averaged to
create the final order for the top 100 companies.
    "We are pleased that Escalon continues as a perennial on FORTUNE's list of
fastest growing small public companies" stated Richard J. DePiano, Chairman
and CEO "It's an honor to be recognized in this group and a reflection of our
focused business strategies and the tremendous work and dedication by our
management team and entire staff."
    Although Fortune lists Escalon as having 64 total employees the number has
grown to 180 employees to date due in part to the Company's acquisition of
Drew-Scientific in July of 2004.
    Drew Scientific, formerly based in the U.K., now based in Texas, with
additional manufacturing operations in the U.K. and Connecticut, is a
diagnostics company specializing in the design, manufacture, sale and
distribution of analytical systems for laboratory testing worldwide.  Drew
Scientific provides instrumentation and consumables for the diagnosis and
monitoring of medical disorders in the areas of diabetes, cardiovascular
diseases and hematology, as well as veterinary hematology and blood chemistry.
    Founded in 1987, Escalon develops, markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices.  Drew Scientific, which operates as a separate division, provides
instrumentation and consumables for the diagnosis and monitoring of medical
disorders in the areas of diabetes, cardiovascular diseases and hematology, as
well as veterinary hematology and blood chemistry.  The Company seeks to
utilize strategic partnerships to help finance its development programs and is
also seeking acquisitions to further diversify its product line to achieve
critical mass in sales and take better advantage of the Company's distribution
capabilities.  Escalon has headquarters in Wayne, Pennsylvania and
manufacturing operations in Long Island, New York, New Berlin, Wisconsin,
Dallas, Texas, Oxford, Connecticut and Barrow Furness, U.K.

    Note: This press release contains statements that are considered
forward-looking under the Private Securities Litigation Reform Act of 1995,
including statements about the Company's future prospects.  They are based on
the Company's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially.  The
uncertainties and risks include whether the Company is able to improve upon
the operations of the Company's business units, generate cash and identify,
finance and enter into business relationships and acquisitions, including the
exchange offer of Drew Scientific, uncertainties and risks related to new
product development, commercialization, manufacturing and market acceptance of
new products, marketing acceptance of existing products in new markets, the
continuity of royalty revenue, research and development activities, including
failure to demonstrate clinical efficacy, delays by regulatory authorities,
scientific and technical advances by the Company or third parties,
introduction of competitive products, third party reimbursement and physician
training as well as general economic conditions.  Further information about
these and other relevant risks and uncertainties may be found in the Company's
report on Form 10-K, and its other filings with the Securities and Exchange
Commission, all of which are available from the Commission as well as other
sources.

Link to this page: